JIUN-KAE JACK LEE to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.395
-
Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396.
Score: 0.086
-
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90.
Score: 0.082
-
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97.
Score: 0.070
-
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20; 101(10):708-20.
Score: 0.066
-
Accrual strategies for phase I trials with delayed patient outcome. Stat Med. 1999 May 30; 18(10):1155-69.
Score: 0.033
-
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996 Jan; 14(1):287-95.
Score: 0.026
-
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
Score: 0.024
-
Polyamine measurements in the uterine cervix. J Cell Biochem Suppl. 1997; 28-29:125-32.
Score: 0.007